Gilgamesh Pharmaceuticals logo

Gilgamesh Pharmaceuticals

Emerging

Clinical-stage psychedelic pharma developing novel psilocybin-derived bretisilocin in Phase 2 for depression; first YC-backed psychedelics company competing with COMPASS Pathways.

30
AI Score
Grade D↑ Trending
AI Visibility Score (Beta)
HealthcareWebsiteUpdated March 2026

Company Overview

About Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing novel psychedelic-derived compounds for treatment-resistant depression, anxiety, and stress-related psychiatric disorders — pursuing a drug discovery approach that modifies psychedelic molecular structures to optimize therapeutic effects (efficacy, duration) while retaining or modifying the subjective psychedelic experience. Founded by Jonathan Sporn MD, Dalibor Sames PhD, Andrew Kruegel PhD, Jeff Witkin PhD, and Mike Cunningham PhD, Gilgamesh was the first Y Combinator-backed company in the psychedelic therapeutics space.

Business Model & Competitive Advantage

Gilgamesh's lead compound bretisilocin (GM-2505) is a novel psilocybin-derived molecule in Phase 2 clinical trials for major depressive disorder, positioned as a potential best-in-class psychedelic compound with optimized pharmacokinetics. The company's scientific founders from Columbia University brought expertise in psychedelic pharmacology and medicinal chemistry that enables rational drug design rather than simply repurposing existing natural psychedelics like psilocybin. The differentiated compound IP strategy creates defensible pharmaceutical assets rather than relying on natural compound exclusivity.

Competitive Landscape 2025–2026

In 2025, Gilgamesh competes in the psychedelic medicine market with COMPASS Pathways (psilocybin for treatment-resistant depression, furthest along in clinical trials), Usona Institute (psilocybin non-profit research), MindMed (LSD and MDMA derivatives), and Lykos Therapeutics (MDMA-assisted therapy) for psychedelic-derived psychiatric treatment development. The FDA declined to approve MDMA-assisted therapy in 2024 (Lykos), creating caution around psychedelic clinical timelines, while COMPASS continues Phase 3 trials for psilocybin. Gilgamesh's novel compound approach (not psilocybin itself) provides a distinct regulatory and IP path. The 2025 strategy focuses on Phase 2 data readouts for bretisilocin, building clinical evidence for the compound's differentiated profile, and advancing toward a Phase 3 pivotal trial design.

Curated content • Fact-checked and verified

Recent Activity

View all →

Key Differentiators

Emerging Innovator

Gilgamesh Pharmaceuticals is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

30
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Browser Use logo

Browser Use

Developer Tools
B2bDeveloper ToolsPlatformSaasStartup

Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom

Oracle Health logo

Oracle Health

Healthcare
HealthtechNorth AmericaB2b

Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve

athenahealth logo

athenahealth

Healthcare
B2bCloud NativeEnterpriseErpHealthtechNorth AmericaSaas

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

Revvity logo

Revvity

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid

For Gilgamesh Pharmaceuticals

Claim This Profile

Are you from Gilgamesh Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Gilgamesh Pharmaceuticals Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Gilgamesh Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →